Benzinga | Sep 24, 2020 07:09AM EDT

Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial Of Telaglenastat In Combination With Chemoimmunotherapy To Treat Aggressive Form Of Lung Cancer

- Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard-of-care treatment in front-line setting amongpatients with non-small cell lung cancer and a mutation in the KEAP1/NRF2 pathway

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced treatment of the first patient in a randomized Phase 2 non-small cell lung cancer (NSCLC) clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with pembrolizumab, carboplatin and pemetrexed. The KEAPSAKE study will evaluate the safety and anti-tumor activity of telaglenastat plus standard-of-care immunotherapy as front-line therapy among patients with stage IV non-squamous NSCLC whose tumors have a KEAP1 or NRF2 mutation determined by next-generation sequencing.